Efficacy of Ceftibut3en + VNRX-5236 in the murine UTI model

StatusFinished
Effective start/end date1/06/18 → 31/01/19

Funding

  • VenatoRx Pharmaceuticals, Inc.: $101,627.94
View all
View less

Keywords

  • Other